Production (Stage)
Arrowhead Pharmaceuticals, Inc.
ARWR
$15.13
-$0.26-1.69%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 370.45M | -173.09M | -170.54M | -170.79M | -125.30M |
| Total Depreciation and Amortization | 6.08M | 5.24M | 5.03M | 4.78M | 4.53M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 38.00M | 29.02M | 20.34M | 25.95M | 25.03M |
| Change in Net Operating Assets | 45.53M | -7.44M | 7.95M | 24.64M | 3.37M |
| Cash from Operations | 460.05M | -146.27M | -137.22M | -115.42M | -92.38M |
| Capital Expenditure | -5.30M | -7.52M | -24.29M | -14.45M | -34.08M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -414.92M | 84.43M | -198.63M | 21.40M | -234.86M |
| Cash from Investing | -420.21M | 76.91M | -222.92M | 6.95M | -268.94M |
| Total Debt Issued | -- | -- | 392.00M | -- | -- |
| Total Debt Repaid | -151.63M | -- | -- | -- | -- |
| Issuance of Common Stock | 244.01M | 634.00K | 223.00K | 387.00K | 430.78M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 20.00M | -3.13M | 50.00M | -- |
| Cash from Financing | 92.38M | 20.63M | 389.09M | 50.39M | 430.78M |
| Foreign Exchange rate Adjustments | -402.00K | -68.00K | 4.34M | -223.00K | 26.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 131.82M | -48.80M | 33.29M | -58.31M | 69.49M |